Details of the Drug Combinations

General Information of This Drug (ID: DMAOL2S)

• Drug Name: Voriconazole (DMAOL2S)
• Synonyms: VCZ; Vfend; Pfizer brand of voriconazole; UK 109496; Voriconazole in combination with MGCD290; DRG-0301; UK 109,496; UK-109496; VFEND (TN); Vfend (TN); Vfend, Voriconazole; UK-109,496; Voriconazole [USAN:INN:BAN]; Voriconazole (JAN/USAN/INN); (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol; (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-Difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol; VRC

Indication

Aspergillosis; ICD 11: 1F20; Status: Approved [1]; Candidiasis; ICD 11: 1F23; Status: Approved [1]; Fusariosis; ICD 11: N.A.; Status: Approved [1]; Invasive aspergillosis; ICD 11: 1F20.0; Status: Approved [2]; Invasive candidiasis; ICD 11: 1F23; Status: Approved [1]; Neuroaspergillosis; ICD 11: N.A.; Status: Approved [1]; Candidemia; ICD 11: 1F23.3Y; Status: Investigative [1]; Esophageal candidiasis; ICD 11: N.A.; Status: Investigative [1]

• Therapeutic Class: Antifungal Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Voriconazole + Marizomib	DCJ3PKI	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Voriconazole + Idarubicin	DCDPCSJ	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Anidulafungin + Voriconazole	DCY6XBV	Anidulafungin	Aspergillosis	[4]
Anidulafungin + Voriconazole	DC8PJGI	Anidulafungin	Fungal infection	[5]
Clarithromycin + Voriconazole	DCWR1YI	Clarithromycin	B-cell Malignancies	[6]
Cobicistat + Voriconazole	DCVZ9OE	Cobicistat	Human Immunodeficiency Virus Type 1 (HIV-1) Infection	[7]
Erythromycin + Voriconazole	DCE4W6M	Erythromycin	B-Cell Chronic Lymphocytic Leukemia	[8]
Micafungin + Voriconazole	DC21BGZ	Micafungin	Stem Cell Transplantation	[9]
Voriconazole + Atazanavir	DCZAJNU	Atazanavir	Human Immunodeficiency Virus Type 1 (HIV-1)	[10]
Voriconazole + Caspofungin	DC8YKF6	Caspofungin	Infection	[11]
Voriconazole + Caspofungin	DCER6ES	Caspofungin	Candidiasis, Invasive	[12]
Voriconazole + Fluconazole	DCFO6JI	Fluconazole	Fungal Infection	[13]
Voriconazole + Efavirenz	DCWQS8Z	Efavirenz	Efavirenz, Metabolism and Pharmacokinetics Changes	[14]
Voriconazole + Gilteritinib	DC2I7P5	Gilteritinib	Acute Myeloid Leukemia	[15]
Voriconazole + SCY-078	DCNCFP6	SCY-078	Invasive Pulmonary Aspergillosis	[16]
Anidulafungin + Voriconazole	DCCNNIS	Anidulafungin	Invasive Candidiasis	[17]
Voriconazole + Natamycin	DCYIBM8	Natamycin	Corneal Ulcer	[18]
Voriconazole + Amphotericin B	DCZ2RUT	Amphotericin B	Blastomycosis	[19]

References

• [1] Voriconazole FDA Label
• [2] Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009 Apr;42(2):148-53.
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT00531479) Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
• [5] Clinical pipeline report, company report or official report of Pfizer.
• [6] ClinicalTrials.gov (NCT04551963) Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
• [7] ClinicalTrials.gov (NCT05458102) Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
• [8] ClinicalTrials.gov (NCT02381080) Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
• [9] ClinicalTrials.gov (NCT01950507) Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
• [10] ClinicalTrials.gov (NCT00833482) Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
• [11] ClinicalTrials.gov (NCT00238355) Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
• [12] ClinicalTrials.gov (NCT00413218) Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
• [13] ClinicalTrials.gov (NCT01503515) Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
• [14] ClinicalTrials.gov (NCT01104376) Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
• [15] ClinicalTrials.gov (NCT02014558) Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
• [16] ClinicalTrials.gov (NCT03672292) Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
• [17] ClinicalTrials.gov (NCT00689338) Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
• [18] ClinicalTrials.gov (NCT02731638) Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
• [19] ClinicalTrials.gov (NCT02283905) Amphotericin-B and Voriconazole for Pulmonary Blastomycosis